XML 55 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders’ Equity (Tables)
12 Months Ended
Dec. 31, 2024
Shareholders’ Equity [Abstract]  
Schedule of Significant Inputs into Black-Scholes Valuation Model The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:
   5.5 Years
June
Warrants
   2 Years
June
Warrants
 
Term   5.5 years    2 years 
Dividend   
-
    
-
 
Expected volatility   44.77%   44.77%
Risk-free rate   3.95%   4.28%
Stock price  $1.97   $1.97 
   2 Years
July
Warrants
 
Term   2 years 
Dividend   
-
 
Expected volatility   61.60%
Risk-free rate   3.86%
Stock price  $1.65 
Schedule of Outstanding Warrants

Total outstanding warrants as of December 31,2024, are as follow:

 

   Number of
warrants
  Exercise
price
  Period left
in years
Warrants May 2023  66,127  $4.625  3.9
Warrants December 2023  1,360,170  $1.18 - $1.47  4.5
Warrants June 2024  1,069,647  $2 - $3.43  5.0
Warrants July 2024  2,069,317  $2.5 - $1.75  1.75
Other  36,792  $10.27 - $50  1.50 - 2.4
Outstanding as of December 31, 2024  4,602,053      
Schedule of Awards Granted During the years ended December 31, 2024, and December 2023, the following awards were granted:
Award Type (2015 Plan)   Number of
Awards in
2024
    Number of
Awards in
2023
    Vesting Conditions   Expiration Date
Options     -       400     Over 4 years from grant date-25% every year (from the second year- 2.08% each month)   10th anniversary of Grant Date
RSU     -       45,100     Over 3 years from grant date    
Schedule of Information Regarding Number of Ordinary Shares Issuable upon Outstanding Options and Exercisable Options A summary of the Company’s share option activity under option plans is as follows:
   Number of
Options
   Weighted-
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life
 
Outstanding – January 1, 2024   87,764   $3.63    4.11 
Granted   
-
   $
-
    - 
Exercised   (22,809)  $0.96    - 
Forfeited   (2,277)  $9.58    - 
                
Outstanding – December 31, 2024   62,678   $4.38    3.4 
                
Exercisable – December 31, 2024   59,721   $3.56    2.7 
Schedule of Information Regarding Number of Ordinary Shares Issuable upon Outstanding Options and Exercisable Options The following table summarize information as of December 31, 2024, regarding the number of ordinary shares issuable upon outstanding options and exercisable options:
Exercise price  Options
outstanding as of
December 31,
2024
   Weighted
average
remaining
contractual
life (years)
   Options
exercisable as of
December 31,
2024
   Weighted
average
remaining
contractual
life (years)
 
0.64   24,586    0.61    24,586    0.61 
1.06   25,936    3.6    25,936    3.60 
1.48   400    8.71    200    8.71 
5.78   4,000    5.98    2500    4.79 
13.62   3,894    6.41    3,830    6.41 
40.00   3,862    7.69    2,669    7.67 
    62,678         59,721      
The following table summarize information as of December 31, 2023, regarding the number of ordinary shares issuable upon outstanding options and exercisable options:
Exercise price  Options
outstanding as of
December 31,
2023
   Weighted
average
remaining
contractual
life (years)
   Options
exercisable as of
December 31,
2023
   Weighted
average
remaining
contractual
life (years)
 
0.64   30,309    1.61    30,309    1.61 
1.06   43,461    4.44    43,402    4.43 
1.48   400    9.71    100    9.71 
5.78   5,500    8.96    1,750    8.96 
13.62   3,894    7.41    2,524    7.41 
40.00   4,200    8.72    1,979    8.72 
    87,764         80,064      
Schedule of Share-based Compensation Expense for Share Options and RSUs Share-based compensation expense for share options in the consolidated statements of comprehensive loss is summarized as follows:
   Year Ended
December 31,
 
   2024   2023 
Cost of revenues   2    3 
Research and development   4    23 
Sales and marketing   2    11 
General and administrative   6    11 
Total Share-based compensation expense   14    48 

Share-based compensation expense for RSUs in the consolidated statement of comprehensive loss is summarized as follows:

 

   Year Ended
December 31
 
   2024   2023 
   U.S. dollars in thousands 
Cost of revenues   10    9 
Research and development   18    53 
Sales and marketing   36    47 
General and administrative   259    220 
Total Share-based compensation expense   323    329 
Schedule of Awards Granted

A summary of the Company’s RSUs activity under option plans is as follows:

 

   Year ended
December 31, 2024
 
   Number of
RSUs
   Weighted-
Average
Grant
Date Fair
Value
 
RSUs outstanding at the beginning of the year   71,280   $10.35 
Granted during the year   
-
      
Vested during the year   (28,228)   8.44 
Forfeited during the year   (6,798)   7.44 
Outstanding at the end of the year   36,254   $12.38